Weiss Ratings Reaffirms Sell (E+) Rating for Prime Medicine (NASDAQ:PRME)

Prime Medicine (NASDAQ:PRME)‘s stock had its “sell (e+)” rating reaffirmed by research analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of Prime Medicine from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Prime Medicine Price Performance

Shares of PRME opened at $5.33 on Friday. Prime Medicine has a 1-year low of $1.11 and a 1-year high of $6.94. The firm has a market capitalization of $717.26 million, a P/E ratio of -3.42 and a beta of 2.65.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.